modelZidovudineLamivudineAndA
Extends from Pharmacolibrary.Drugs.ATC.J.J05AR04.
Information
| name: | ZidovudineLamivudineAndAbacavir | |
| ATC code: | J05AR04 | route: | oral |
| compartments: | 1 | |
| dosage: | 750 | mg |
| volume of distribution: | 1.3 | L |
| clearance: | 25 | L/h |
| other parameters in model implementation | ||
This is a fixed-dose combination antiretroviral medication containing zidovudine, lamivudine, and abacavir. It is used in the treatment of HIV infection to suppress viral replication as part of highly active antiretroviral therapy (HAART). All three agents are nucleoside reverse transcriptase inhibitors (NRTIs) and act synergistically to inhibit HIV reverse transcriptase. The combination is approved and widely used today as part of standard HIV management regimens.
Pharmacokinetics
Pharmacokinetic parameters reported in healthy HIV-negative adult volunteers after single oral administration of the fixed-dose combination tablet containing zidovudine 300 mg, lamivudine 150 mg, and abacavir 300 mg.
References
Kasirye, P, et al., & Walker, AS (2012). Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. Clinical pharmacology and therapeutics 91(2) 272–280. DOI:10.1038/clpt.2011.225 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22190066
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)